During Phase I, participants will be given two GBP511 doses, spaced 28 days apart, across low, medium, and high dosage groups. Credit: SK bioscience / PR Newswire. SK bioscience has initiated an ...
The trial’s objective is to assess immune responses, tolerability, safety, and ER-100’s effect on various visual assessments. Credit: Komsan Loonprom / Shutterstock.com. Life Biosciences (Life Bio) ...
CalciMedica is terminating its Phase II trial on its lead asset, Auxora in AKI with associated AHRF. Image credit: Visual Print via ShutterStock.com. CalciMedica has terminated a Phase II study on its ...
Ibsrela is currently indicated for the treatment of irritable bowel syndrome with constipation in adults. Credit: Prostock studio / Shutterstock.com. Ardelyx has dosed the first patient in the ACCEL ...
Real-world evidence (RWE) empowers payers and providers to make more informed, cost-effective treatment. Read more here: ...
Intellia Therapeutics has been given the green light to continue dosing in the MAGNITUDE-2 trial. Image credit: Lofix / Shutterstock.com Intellia Therapeutics has been given approval to resume patient ...
William Blair analysts view Elevidys’ three-year outcome as a win for Sarepta, though they remain sceptical on the readout’s sales impact.
Ascletis Pharma has dosed the first participants in a US Phase II trial of ASC30, an oral small molecule GLP-1 receptor agonist, intended for treating type 2 diabetes mellitus.
Rifaximin SSD failed to significantly delay the onset of HE in patients with liver cirrhosis, but Bausch is yet to scrap its development.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results